Scientific Program

Abstract:

Creatv Bio provides innovative liquid biopsy blood tests for cancer screening, cancer prognosis and predicting cancer treatment response. We were the first to discover and research the clinical applications of tumor macrophage fusion cells found in the blood of cancer patients. These tumor macrophage cells are commonly ignored, mis-identified or simply not properly collected by other liquid biopsy techniques.  Our LifeTracDx® blood tests have been shown to collect all tumor macrophage fusion cells, as well as circulating tumor cells, from the blood of cancer patients for numerous drug developments and clinical applications. LifeTracDx® blood tests have been shown to be applicable to all solid tumors, all stages of cancer and all therapy types.
LifeTracDx® liquid biopsies are applicable for cancer screening and providing patient prognosis in parallel from a single blood sampling, including:
(1) Screening for single cancer or pan cancers with high sensitivity even in Stage I.
(2) Detecting minimal residual disease at end of therapy treatment, and (3) Detecting recurrence earlier than standard imaging.
LifeTracDx® liquid biopsies may also provide a spectrum of clinical utilities for patients with cancer, including:
(1) Providing companion/complementary diagnostics (simpler and cheaper than tissue biopsies).
(2) Predicting treatment response in 30 days after a new therapy induction.
(3) Providing prognosis at any time during treatment.
(4) Monitoring patient responses to treatments over time, and
(5) Providing unfragmented tumor DNA for sequencing. Clinical applications of these highly sensitive and specific tests might reduce morbidity and significantly improve patient outcomes.
Our LifeTracDx® blood tests will not only benefit patients, but also suited for cancer drug development and clinical trials.

Audience Take Away Notes:

• The audience will learn about a novel type of circulating cancer biomarker in the blood of patients that had not been previously studied prior to our discovery
• The audience will learn about our ongoing research studies regarding this cancer biomarker in various cancer subtypes and their biological origins in cancer patients
• The audience will learn about the various clinical utilizations established using this novel cancer marker and its clinical applicability in specific cancer screening trials and in predicting drug responses

Biography:

Daniel Adams is Director of Clinical R&D at Creatv Bio, Division of Creatv MicroTech, Inc., and  currently a visiting scientist at Rutgers University, New Jersey. He received BS in Biochemistry-Molecular Biology from University of California Santa Barbara. Before joining Creatv MicroTech in 2007, he was Associate Research Scientist at SBH Sciences, a pre-clinical CRO for cancer drug development. He was first to publish the clinical applications of tumor macrophage fusion cells.  He has been lead author on 20 peer-reviewed publications, 7 co-authorships, and written 4 book chapters on bio-detection of rare analytes and liquid biopsies for cancer screening and cancer diagnostics.